Immune globulin 5% - Octapharma

Drug Profile

Immune globulin 5% - Octapharma

Alternative Names: octagam; Octagam; Octagam 5%; Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders
  • Phase III Multiple sclerosis

Most Recent Events

  • 18 Dec 2013 Phase-III clinical trials in Multiple sclerosis in Bulgaria (IV)
  • 31 May 2013 Octapharma initiates enrolment in a postmarketing trial for Immunodeficiency disorders in USA (NCT01859754)
  • 09 May 2013 Re-launched for Immunodeficiency disorders in Belgium before May 2013 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top